Safety efficacy of open-label dupilumab in adult patients with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE)

被引：0
|
作者：
Thaci, D. [1 ]
Deleuran, M. [2 ]
Bissonnette, R. [3 ]
Bouaziz, J. D. [4 ]
Sun, X. [5 ]
Patel, N. [6 ]
Shumel, B. [5 ]
机构：
[1] Univ Lubeck, Lubeck, Germany
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Innovaderm Res, Montreal, PQ, Canada
[4] Hop St Louis, Paris, France
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Sanofi, Bridgewater, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 183卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P01
引用
收藏
页码：E94 / E94
页数：1
相关论文
共 50 条
  • [41] SAFETY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Sierka, D.
    Coleman, A.
    Gherardi, G.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S92 - S92
  • [42] Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial
    Wollenberg, Andreas
    Beck, Lisa
    Deleuran, Mette Sondergaard
    Blauvelt, Andrew
    Thyssen, Jacob
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal
    Rodriguez-Marco, Ainara
    Levit, Noah
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB10 - AB10
  • [43] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study
    Blauvelt, Andrew
    Wollenberg, Andreas
    Beck, Lisa A.
    Chen, Zhen
    Zhang, Meng
    Khokhar, Faisal A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB142 - AB142
  • [44] Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis
    Nettis, Eustachio
    Patella, Vincenzo
    Lombardo, Carla
    Detoraki, Aikaterini
    Macchia, Luigi
    Di Leo, Elisabetta
    Carbonara, Monica
    Canonica, Giorgio W.
    Bonzano, Laura
    ALLERGY, 2020, 75 (10) : 2653 - 2661
  • [45] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman, Emma
    Hussain, Iftikhar
    Chen, Zhen
    Mina-Osorio, Paola
    Rossi, Ana Beatris
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB141 - AB141
  • [46] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E96
  • [47] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Worrell, R.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 29 - 31
  • [48] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
  • [49] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [50] Long-term efficacy of dupilumab in adults with moderate-tosevere atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years
    Thyssen, Jacob P.
    Blauvelt, Andrew
    Lockshin, Benjamin
    Galus, Ryszard
    Lynde, Charles
    Xiao, Jing
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB180 - AB180
12345